Novo Nordisk stock heads into the open after a 2.1% slide
Published on 09/17/2026 at 05:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novo Nordisk stock closed at USD 42.53 in U.S. ADR trading on the NYSE on September 16, 2026, down 2.12% from the prior close. Per NYSE data at MarketWatch, the day’s range ran from a low near USD 41.24 to an intraday high around USD 43.45, with the closing price settling closer to the lower end of that span. The shares continued to trade below recent peaks in a weak session for the stock, even as the broader U.S. equity indices were more mixed.
September 16, 2026 in numbers
Novo Nordisk A/S (ISIN DK0060534915, NYSE: NVO) saw its ADRs in the U.S. close the last completed session at USD 42.53 on September 16, 2026, registering a 2.12% decline versus the prior day’s close. According to price data highlighted by Traders Union, the shares tested support around USD 41.24 during the session before recovering part of the loss into the close. That closing level left the stock visibly below analyst fair-value assessments near USD 105 per share referenced by GuruFocus, underlining the magnitude of the recent pullback.
The session’s weakness was tied in part to corporate developments. Novo Nordisk’s termination of a metabolic and cardiovascular disease collaboration with Ascendis Pharma, announced locally on September 14, 2026, drew attention to the company’s long-acting GLP-1 pipeline. As reported in detail by Sina Finance, the partnership’s end means Ascendis regains rights to once-monthly semaglutide candidates using its TransCon technology, leaving Novo Nordisk focused on weekly GLP-1 formulations in its publicly disclosed pipeline. In parallel, sentiment was shaped by a fresh Sell rating and DKK 265 price target from Deutsche Bank on the company’s Copenhagen-listed shares, as noted by The Globe and Mail, adding pressure to the stock.
Today’s drivers and upcoming events
Today, September 17, 2026, investors face a mix of company-specific and strategic developments that could influence Novo Nordisk’s trading once U.S. markets open. On the innovation side, Novo Nordisk has announced a collaboration with artificial intelligence firm Anthropic to use the Claude platform in accelerating drug discovery and upgrading internal software tools, a tie-up highlighted on its newsroom and covered by outlets such as Sina Finance. The agreement is framed as a way to enhance pipeline productivity and data handling, factors closely watched in the competitive GLP-1 and cardiometabolic treatment markets.
In addition, Novo Nordisk is set to present real-world and clinical data on its Wegovy pill and broader cardiometabolic pipeline, including next-generation amylin-based treatments, at the EASD 2026 meeting. This upcoming scientific and investor engagement was outlined by the company in a press release distributed via GlobeNewswire, with presentations scheduled around the EASD 2026 congress window. These data are poised to offer more detail on how Novo Nordisk positions its obesity and cardiometabolic franchises relative to rivals, making the conference an important backdrop for trading in the coming sessions.
